...
首页> 外文期刊>Nuclear Medicine and Biology >Carbon-11 labeled cathepsin K inhibitors: Syntheses and preliminary in vivo evaluation
【24h】

Carbon-11 labeled cathepsin K inhibitors: Syntheses and preliminary in vivo evaluation

机译:Carbon-11标记的组织蛋白酶K抑制剂:合成和体内初步评估

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Cathepsin K is a cysteine peptidase primarily located in osteoclasts, cells involved in normal growth and remodeling of bone but that are also responsible for bone loss in osteolytic diseases such as osteoporosis. In vivo imaging of cathepsin K may provide a method to assess changes in osteoclast numbers in such disease states. To that end, two high-affinity and selective cathepsin K inhibitors were radiolabeled with carbon-11. In vivo microPET imaging studies demonstrated uptake and prolonged retention of radioactivity in actively growing or remodeling bone regions (e.g., distal ulnar, carpal, distal and proximal humeral, distal femur, proximal tibia, tail vertebrae). Uptake into bone could be blocked by pre- or co-injection of unlabeled ligand, supporting a specific and saturable binding mechanism for radiotracer localization. These proof-of-concept studies indicate that radiolabeled cathepsin K inhibitors may have potential as in vivo imaging radiotracers for assessing changes of osteoclast numbers in osteolytic diseases.
机译:组织蛋白酶K是一种半胱氨酸肽酶,主要位于破骨细胞中,破骨细胞参与骨骼的正常生长和重塑,但也与溶骨性疾病(如骨质疏松症)中的骨丢失有关。组织蛋白酶K的体内成像可能提供一种评估这种疾病状态下破骨细胞数量变化的方法。为此,将两种高亲和力和选择性组织蛋白酶K抑制剂用carbon-11进行了放射性标记。体内microPET成像研究表明,在活跃生长或重塑的骨区域(例如尺骨远端,腕骨,肱骨远端和近端,股骨远端,胫骨近端,尾椎骨)中,放射性的摄取和保留时间延长。预先或共同注射未标记的配体可阻止骨吸收,从而支持放射性示踪剂定位的特异性和饱和结合机制。这些概念验证研究表明,放射性标记的组织蛋白酶K抑制剂可能具有作为体内成像放射性示踪剂的潜力,可用于评估溶骨性疾病中破骨细胞数量的变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号